One To Watch

Tempus AI

Company Overview

A Chicago-based AI and precision medicine company that converts multimodal clinical and genomic datasets into decision-support tools for oncology, now accelerating its position in molecular residual disease diagnostics through a $1.5 billion acquisition of Personalis. Tempus AI, Inc. trades on Nasdaq under the ticker TEM and has built its business around the thesis that the bottleneck in cancer care is not science but data — specifically the failure to integrate molecular, imaging, and clinical records at scale. The pending Personalis deal, announced in July 2026, is the most concrete expression yet of that thesis, adding tumor-informed MRD detection to a platform that was already one of the broadest in precision oncology.

Headquarters and Global Presence

Tempus AI is headquartered in Chicago, Illinois, and listed on Nasdaq (TEM). Its commercial infrastructure spans genomic testing services, AI-driven analytics, and pharma partnerships across multiple therapeutic areas, with oncology as the dominant vertical. The company's partnerships with Bristol Myers Squibb, Gilead Sciences, and Boehringer Ingelheim signal a reach that extends well beyond domestic clinical networks into global drug development programs.

Founding and History

Tempus AI was founded in 2015 by Eric Lefkofsky and has since grown into one of the most prominent AI health technology platforms in the United States. The company's evolution has been marked by deepening integration of clinical data infrastructure with commercial genomic testing, culminating in its Nasdaq listing under TEM. The July 2026 agreement to acquire Personalis for approximately $1.5 billion represents its most significant strategic move to date, bringing a specialized MRD diagnostics business into the fold.

Therapy Areas and Focus

Oncology is the organizing logic of Tempus AI's entire platform — the disease area where multimodal data is most heterogeneous, clinical decisions most consequential, and the gap between available information and actionable insight most commercially exploitable. The addition of Personalis extends that focus into minimal residual disease monitoring, a fast-moving segment of oncology diagnostics that tracks whether cancer cells persist after treatment. MRD detection is increasingly recognized as a surrogate endpoint in clinical trials and a real-world tool for guiding treatment de-escalation or intensification. Tempus also operates across other therapy areas where AI-driven decision support adds value, though oncology remains the commercial and scientific anchor.

Technology Platforms and Modalities

The core platform ingests multimodal data — genomic, clinical, imaging, and outcomes — and applies AI to generate decision-support insights for clinicians and drug developers. What differentiates Tempus from pure diagnostics players is the feedback loop: each test and each dataset strengthens the underlying models, creating a compounding data advantage that is difficult to replicate quickly. The acquisition of Personalis adds tumor-informed MRD technology, where sequencing of a patient's primary tumor enables ultra-sensitive liquid biopsy tests that can detect residual disease at very low variant allele frequencies. Personalis' NeXT Personal MRD test is the anchor asset here, and integrating it with Tempus' existing platform creates a more complete molecular monitoring capability across the cancer treatment continuum.

Key Pipeline and Programs

Tempus AI is a diagnostics and data platform company rather than a drug developer, so its key programs are commercial and clinical genomic testing products rather than investigational drugs. The NeXT Personal MRD test, acquired via the pending Personalis deal, is the headline asset — a tumor-informed liquid biopsy product designed to detect molecular residual disease with high sensitivity, relevant in colorectal cancer, breast cancer, and other solid tumor settings. Personalis delivered 10,384 clinical tests in the second quarter of 2026 alone, a 33% increase in test volume quarter-on-quarter, and posted preliminary Q2 revenue of $22.4 million, indicating the product is already scaling commercially ahead of the deal closing. Tempus' existing genomic testing and AI analytics suite serves both clinical and pharmaceutical research customers, with pharma partnerships structured around using Tempus data to inform and accelerate oncology drug development programs.

Recent Developments

The defining event of 2026 is the July 20 announcement of Tempus AI's agreement to acquire Personalis for approximately $1.5 billion — a 28% premium to Personalis' 30-day volume-weighted average price — with closing expected in late 2026 or early 2027, pending shareholder and regulatory approvals.

Key Personnel

Eric Lefkofsky serves as founder of Tempus AI and has been the driving strategic force behind the company since its founding in 2015. Lefkofsky is a serial entrepreneur whose vision for Tempus was shaped by a conviction that oncology's data problem — not its science problem — was the more tractable and commercially significant challenge to solve.

Strategic Partnerships

Tempus has assembled an unusually dense portfolio of pharma partnerships for a diagnostics and data company. The pattern — multiple top-ten pharma companies returning for expanded, multi-year deals — suggests Tempus' data assets are proving genuinely useful in drug development, rather than functioning merely as headline partnerships.

FAQ Section

The $1.5 billion Personalis acquisition, announced July 20, 2026, brings tumor-informed MRD technology — specifically the NeXT Personal MRD test — into Tempus' AI-driven precision oncology platform. MRD detection fills a critical gap: it tracks whether cancer cells persist after treatment, informing decisions about therapy continuation or de-escalation. Personalis was already delivering over 10,000 clinical tests per quarter and growing at 33% quarter-on-quarter, so the asset arrives with commercial momentum rather than development-stage risk.

MRD testing uses liquid biopsy to detect residual tumor DNA in blood after treatment, identifying patients who appear disease-free by conventional imaging but retain microscopic disease burden. The clinical implication is significant: MRD-positive patients face higher relapse risk and may warrant intensified treatment, while MRD-negative patients may be candidates for de-escalation. Regulators and pharma companies are increasingly accepting MRD as a surrogate endpoint in oncology trials, which makes owning a validated MRD platform strategically valuable beyond the clinical diagnostic market.

Tempus is not a pure-play diagnostics company — its commercial model is built on the interaction between testing volume and AI model improvement. Each new test and clinical data point strengthens the underlying algorithms, creating a compounding data advantage that a company entering the market later would struggle to replicate. The multimodal approach — integrating genomic, imaging, and clinical outcomes data — also allows insights that single-modality sequencing companies cannot generate. That breadth is what attracts pharma partners seeking R&D infrastructure rather than just test results.

The NeXT Personal MRD test is a tumor-informed liquid biopsy product from Personalis that sequences a patient's primary tumor to build a personalized variant panel, then uses that panel to detect residual cancer DNA in blood with high sensitivity. It is a commercial product, not a development-stage asset — Personalis delivered 10,384 clinical tests in Q2 2026, a 33% increase in volume quarter-on-quarter, generating preliminary revenue of $22.4 million in the quarter. Integrating it with Tempus' existing platform and commercial infrastructure is the strategic rationale for a $1.5 billion deal at a 28% premium to Personalis' 30-day average price.

Oncology is the dominant focus across both the clinical diagnostics and pharma partnership businesses, with MRD, genomic tumor profiling, and AI-driven treatment decision support all operating within the cancer space. The company also applies its AI and data infrastructure to other therapy areas, though the commercial weight and pipeline of pharma partnerships — Gilead, Bristol Myers Squibb, Boehringer Ingelheim — are concentrated in oncology drug development. The Personalis acquisition deepens rather than diversifies that oncology concentration, signaling a deliberate choice to own more of the cancer care data continuum rather than expand horizontally.

Tempus is a commercial-stage company with active revenue streams from genomic testing and pharma data partnerships — not a pre-revenue platform waiting on regulatory clearances. The immediate milestone is closing the Personalis acquisition, expected in late 2026 or early 2027 subject to shareholder and regulatory approvals. Beyond integration, the question is whether the combined MRD and multimodal AI platform can expand MRD's role as a trial endpoint and clinical standard, which would create a much larger addressable market than diagnostic testing alone.

Want to Update your Company's Profile?